Medscape News
MILAN, Italy
A combination of 2 urine-based genetic biomarkers predicts prostate cancer better than either biomarker alone and better than the standard serum prostate-specific antigen (PSA), according to a new study.
The 2 markers, PCA3 and the TMPRSS2:ERG gene fusion "can help stratify men for risk of cancer, significant cancer, and high-grade cancer at biopsy," said Jack Groskopf, PhD, director of oncology research and development at Hologic Gen-Probe in San Diego, California.
The company is currently developing both biomarkers.
"We're hoping to show that the urine test results can help predict the probability of a positive biopsy and the probability that the biopsy will find clinically significant cancer that needs to be treated," Dr. Groskopf told Medscape Medical News.
Read More
